Unichem Laboratories Ltd

Unichem Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Unichem Laboratories Ltd

₹ 586 -0.20%
03 Jul 4:01 p.m.
unichemlabs.com BSE: 506690 NSE: UNICHEMLAB
About

Unichem Laboratories Ltd is involved in pharmaceuticals
in Generics, APIs and Contract Manufacturing (CMO) areas.[1]

Key Points

Therapeutic Areas
The company manufactures and markets APIs and pharmaceutical formulations as branded & non-branded generics. The company’s products cater to diverse therapeutic areas such as cardiology, gas, diabetology, gastroenterology psychiatry, neurology, antibacterial, anti-infective, and pain management. [1]

Website BSE NSE
  • Market Cap ₹ 4,122 Cr.
  • Current Price ₹ 586
  • High / Low ₹ 950 / 512
  • Stock P/E 30.0
  • Book Value ₹ 348
  • Dividend Yield 0.00 %
  • ROCE 6.36 %
  • ROE 5.71 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has delivered good profit growth of 29.2% CAGR over last 5 years

Cons

  • Company has a low return on equity of -0.94% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
370 310 329 302 402 423 416 466 432 446 507 533 587
302 311 347 345 386 395 407 435 406 403 452 448 503
Operating Profit 68 -1 -18 -43 16 28 9 31 25 44 55 86 84
OPM % 18% -0% -6% -14% 4% 7% 2% 7% 6% 10% 11% 16% 14%
14 8 4 16 -28 9 6 79 -119 4 9 14 9
Interest 2 3 5 4 6 6 7 6 5 4 5 7 5
Depreciation 23 25 28 31 30 29 29 32 27 28 32 31 30
Profit before tax 58 -21 -47 -61 -47 2 -22 73 -126 15 27 62 58
Tax % -23% 13% 50% 4% -6% 132% 12% -0% 3% 38% 9% 6% 8%
71 -23 -71 -64 -44 -1 -24 73 -129 9 25 58 53
EPS in Rs 10.15 -3.32 -10.04 -9.08 -6.29 -0.10 -3.48 10.40 -18.37 1.32 3.50 8.22 7.52
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
1,133 1,202 1,333 698 815 1,180 1,104 1,235 1,270 1,343 1,705 2,111
956 1,100 1,169 738 942 1,254 1,153 1,144 1,198 1,389 1,605 1,846
Operating Profit 178 101 164 -41 -128 -74 -49 91 72 -46 100 265
OPM % 16% 8% 12% -6% -16% -6% -4% 7% 6% -3% 6% 13%
83 20 15 184 2,735 91 91 50 47 -0 -26 35
Interest 3 3 3 3 8 8 8 5 6 17 23 21
Depreciation 46 41 39 44 51 67 82 84 91 113 113 125
Profit before tax 212 77 137 97 2,548 -58 -48 51 22 -176 -62 155
Tax % 20% 3% 21% -12% 0% -59% 25% 33% -50% 15% 14% 11%
169 75 108 109 2,545 -24 -60 34 33 -202 -70 138
EPS in Rs 18.68 8.31 11.90 11.96 361.82 -3.38 -8.55 4.87 4.70 -28.72 -10.01 19.53
Dividend Payout % 43% 24% 17% 25% 1% -118% -47% 82% 85% -14% 0% 0%
Compounded Sales Growth
10 Years: 6%
5 Years: 14%
3 Years: 18%
TTM: 24%
Compounded Profit Growth
10 Years: 6%
5 Years: 29%
3 Years: 63%
TTM: 591%
Stock Price CAGR
10 Years: 11%
5 Years: 25%
3 Years: 34%
1 Year: 10%
Return on Equity
10 Years: 12%
5 Years: 0%
3 Years: -1%
Last Year: 6%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 18 18 18 18 14 14 14 14 14 14 14 14
Reserves 798 849 936 1,045 2,666 2,606 2,517 2,543 2,604 2,421 2,348 2,437
26 22 36 98 151 200 206 119 349 314 248 460
302 264 283 359 359 323 407 436 351 444 559 659
Total Liabilities 1,145 1,153 1,274 1,521 3,190 3,142 3,145 3,112 3,319 3,193 3,169 3,569
419 416 403 491 578 810 870 884 990 1,257 1,196 1,300
CWIP 91 123 237 250 238 92 330 568 494 147 123 31
Investments 11 41 14 14 901 926 550 392 264 2 1 0
623 574 620 766 1,473 1,313 1,395 1,269 1,571 1,787 1,849 2,239
Total Assets 1,145 1,153 1,274 1,521 3,190 3,142 3,145 3,112 3,319 3,193 3,169 3,569

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
87 78 112 68 -112 -328 20 33 -260 -85 17 -7
36 -52 -85 -132 1,648 -286 -36 -66 100 241 57 -241
-95 -51 -33 59 -881 -2 -62 -121 191 -81 -106 184
Net Cash Flow 28 -25 -7 -4 655 -616 -78 -154 32 75 -33 -64

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 63 58 60 165 124 135 129 74 142 160 131 135
Inventory Days 192 171 184 397 278 278 374 518 527 414 387 418
Days Payable 142 114 131 297 230 182 236 202 161 193 164 170
Cash Conversion Cycle 113 116 113 265 172 231 267 390 508 382 353 382
Working Capital Days 95 89 94 225 200 227 217 194 277 272 217 224
ROCE % 19% 9% 15% 9% 128% -2% -2% 2% 1% -5% 0% 6%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
50.93% 50.94% 50.94% 50.94% 50.94% 70.21% 70.22% 70.22% 70.22% 70.22% 70.22% 70.22%
1.50% 1.71% 1.56% 1.70% 1.62% 0.83% 0.84% 0.90% 0.89% 0.94% 1.05% 0.98%
9.53% 8.70% 8.21% 8.15% 9.65% 10.00% 10.46% 11.26% 11.57% 11.65% 11.63% 11.32%
38.04% 38.67% 39.31% 39.21% 37.80% 18.95% 18.47% 17.63% 17.32% 17.17% 17.11% 17.47%
No. of Shareholders 32,66629,57330,61829,41826,64221,58420,87721,17120,62120,37421,47221,621

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls